List view / Grid view

Dr. Elias Zerhouni

Filter the results

 

Dr. Elias A. Zerhouni (born April 12, 1951) is an Algerian-born American physician scientist radiologist and biomedical engineer. As a world-renowned national and international leader, Zerhouni is widely viewed as one of the leading authorities on emerging trends and issues in biomedical sciences and medical care. He spent much of his career on the faculty of the Johns Hopkins University school of Medicine.

From 1995 to 2002, he served as Executive Vice-Dean of Johns Hopkins School of Medicine and, in 2002, was appointed by President George W. Bush and confirmed by the Senate as the 15th Director of the National Institutes of Health, serving until 2008. In 2009, under the Obama Administration, he served as one of the country’s first presidential science envoys to foster scientific and technologic collaboration with other nations.

He also served as a senior fellow for the Bill and Melinda Gates foundation from 2009 through 2010. Since 2011, he is the President for Global Research and Development at Sanofi, one of the largest multinational pharmaceutical companies in the world.

news

EU approval for Sanofi’s type 2 diabetes treatment

Suliqua is an innovative new combination therapy that has the…

19 January 2017 | By Niamh Marriott, Digital Editor

Suliqua is an innovative new combination therapy that has the potential to address significant unmet needs for people living with type 2 diabetes in Europe

news

FDA approval for Sanofi’s Soliqua to treat type 2 Diabetes

Soliqua 100/33 is the combination of Lantus (insulin glargine 100…

29 November 2016 | By Niamh Louise Marriott, Digital Editor

Soliqua 100/33 is the combination of Lantus (insulin glargine 100 Units/mL) and lixisenatide, a GLP-1 receptor agonist, studied in a Phase 3 program...

news

Positive topline results from two Phase III dupilumab studies

Sanofi and Regeneron have announced positive topline results from two…

1 April 2016 | By Victoria White

Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).

news

Positive top-line results in second LixiLan Phase III study

The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1…

14 September 2015 | By Victoria White

The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...

news

Sanofi and Regeneron announce positive results from Phase 2b study of Dupilumab in patients with moderate-to-severe atopic dermatitis

Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron…

10 July 2014 | By Sanofi

Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema.